O-RADS超声v2022与v2019及ADNEX模型对附件肿物风险分层的诊断效能比较
本研究回顾性分析434例经手术病理证实的附件肿物女性,三位放射科医师分别按O-RADS超声v2019和v2022进行分级,并计算ADNEX模型恶性风险。结果显示v2022在≥4类阈值下AUC为0.935,敏感度98.3%,特异度70.8%。三者AUC无显著差异,但v2022特异度数值更高且阅片者间一致性更好。
要点
- O-RADS超声v2022可作为日常附件肿物风险分层的精化方案,重复性优于v2019。
- 以≥4类为恶性阈值时v2022敏感度98.3%,适合作为排除恶性的筛查分级。
- v2022特异度在数值上高于v2019和ADNEX,有助减少假阳性转诊。
核心结论
- O-RADS超声v2022诊断效能与v2019及ADNEX模型相当,AUC分别为0.935、0.919、0.930,差异无统计学意义。
- v2022较v2019和ADNEX展现出数值上更高的特异度,以及较v2019更高的阅片者间和阅片者内一致性。
研究设计与样本
- 回顾性分析前瞻性收集数据,纳入2022年1月至2023年12月行盆腔超声且有手术病理证实的434例附件肿物女性。
- 良性192例,恶性242例;三位放射科医师独立进行O-RADS超声v2019和v2022分级,以共识分类用于诊断效能分析。
- ADNEX恶性风险使用官方在线计算器计算并纳入血清CA125。
- 诊断效能采用受试者工作特征曲线分析评估,阅片者一致性采用加权κ统计量评估。
诊断标准与关键数值
- O-RADS超声v2022以≥4类为阈值时AUC为0.935,敏感度98.3%,特异度70.8%,准确度86.2%。
- O-RADS超声v2022、v2019和ADNEX模型的AUC分别为0.935、0.919、0.930,三者差异无统计学意义。
- 与v2019和ADNEX相比,v2022表现出数值上更高的特异度;与v2019相比,v2022的阅片者间和阅片者内一致性均更高。
临床应用与阅片要点
- 在日常附件肿物超声报告中可采用O-RADS v2022分级,以≥4类作为提示恶性风险升高的报告阈值。
- v2022较高的阅片者间一致性有利于不同医师报告结果的可比性,适合在科室内部推广使用。
- ADNEX模型需结合血清CA125计算,在无条件获取CA125或不便使用在线计算器的场景下可优先采用O-RADS超声分级。
局限性
- 本研究为回顾性分析,仅纳入有手术病理结果的病例,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the diagnostic performance and reproducibility of the Ovarian-Adnexal Reporting and Data System (O-RADS) ultrasound version 2022 (v2022) compared with O-RADS ultrasound version 2019 (v2019) and the Assessment of Different NEoplasias in the adneXa (ADNEX) model for adnexal mass risk stratification.
METHODS: This retrospective analysis of prospectively collected data included 434 women with surgically confirmed adnexal masses who underwent pelvic ultrasound from January 2022 to December 2023. Three radiologists independently assigned O-RADS ultrasound v2019 and v2022 categories, with consensus classifications used for diagnostic performance analysis. ADNEX malignancy risks were calculated using the official online calculator with serum CA125 included. Diagnostic performance was assessed using receiver operating characteristic analysis, and reader agreement using weighted κ statistics.
RESULTS: The cohort included 192 benign and 242 malignant lesions. O-RADS ultrasound v2022 showed excellent discriminatory performance, with an area under the curve of 0.935, sensitivity of 98.3%, specificity of 70.8%, and accuracy of 86.2% at the threshold of category ≥ 4. The areas under the curve of O-RADS ultrasound v2022, O-RADS ultrasound v2019, and ADNEX were not significantly different: 0.935, 0.919, and 0.930, respectively. Compared with v2019 and ADNEX, v2022 showed numerically higher specificity. Compared with v2019, v2022 also showed consistently higher inter- and intra-reader agreement.
CONCLUSION: O-RADS ultrasound v2022 demonstrated diagnostic performance comparable to that of v2019 and the ADNEX model, while showing numerically higher specificity and greater reader agreement. These findings support v2022 as a refined and reproducible framework for ultrasound-based adnexal mass risk stratification.
引用
- Wei, Yang, Li, et al. Refined risk stratification with O-RADS ultrasound v2022: Diagnostic performance compared with v2019 and the ADNEX model. Eur J Radiol. 2026. PMID: 42508276. doi:10.1016/j.ejrad.2026.113102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。